Glrx and GSylation have been implicated in a wide range of diseases, such as Parkinson’s [9,10,11], retinal degenerative disorders [12,13,14], non-alcoholic fatty liver disease [15,16,17], lung disease [18,19], and CVDs. This evidence concerns the gene GLRX and metabolic dysfunction-associated steatotic liver disease.